ArticleBMC public health2025
Determinants and sequelae of smoking: prevalence, incidence, and cessation among male adults in Abu dhabi, United Arab Emirates - a retrospective cohort study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cigarette smoking, smoking cessation, and overactive bladder (OAB): a cross-sectional research of NHANES 2011 to 2018.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking represents a significant public health challenge and remains one of the leading causes of preventable morbidity and mortality worldwide. This study aimed to determine the prevalence and cumulative risk of smoking among adult males in Abu Dhabi, and to assess the factors influencing the initiation, cessation, and maintenance of smoking, as well as the association of smoking status with other health conditions.
methodsThis retrospective cohort study included a total of 4361 male subjects aged 18 to 93 years who participated in a comprehensive screening program (Weqaya) conducted in Abu Dhabi ambulatory healthcare services between 2011 and 2013. Of those participants, 3865 had a documented smoking status at baseline (2011-2013) and were followed up for an average of 8.9 years (range: 0-12 years). Data were initially collected from the electronic medical records (EMR), and follow-up data were collected again from their medical records in the Cerner system in 2023. At the end of the follow-up in 2023, the smoking status was documented in 3360 participants, based on their last encounter documented in the EMR. Statistical analysis included descriptive statistics, Chi-square tests, and logistic regression.
resultsThe baseline prevalence of smoking among male adults was 24.5%, whereas the prevalence at the end of the follow-up period was 21%. The cumulative risk of smoking, which is the reporting of smoking at any point in time, was 45%, with the highest risk observed in adults aged 30-39. Young age and lower cholesterol level were the main determinants of starting smoking. The predictors of quitting smoking were younger age, lower systolic blood pressure, higher cholesterol, lower high-density lipoprotein (HDL), lower glomerular filtration rate (GFR), and lower vitamin D levels. The history of acute coronary syndrome (ACS) was a determinant for maintaining smoking cessation. Continuing smoking is associated with a higher risk of developing diabetes mellitus (DM), stroke, acute coronary syndrome (ACS), psychiatric illness, non-alcoholic fatty liver disease (NAFLD), and peripheral artery disease (PAD), while smoking cessation is associated with a reduced risk of those conditions.
conclusionsThe study confirms smoking's health burden in Abu Dhabi and its association with various health risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.